The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD).

Lineage Cell Therapeutics, has announced the upcoming presentation of two-year outcomes from a Phase 1/2a study of RG6501, also known as OpRegen.

In Durham, N.C., Atsena Therapeutics announced that the second group in their LIGHTHOUSE study has started receiving doses of ATSN-201.

Biotechnology firm Ocugen, Inc. has announced the completion of dosing for the initial group in its Phase 1/2 clinical trial for OCU410.

AI-driven drug discovery firm Expert Systems has reached a key milestone with its partner, Eilean Therapeutics, by initiating the first phase of clinical trials for balamenib (ZE63-0302).

Faron Pharmaceuticals, a biopharmaceutical firm specializing in innovative immunotherapies, has announced the scheduling of a virtual BEXMAB study update session.

The clinical trial will explore Gynica's proprietary cannabinoid-based formulations, which are administered intravaginally, leveraging the therapeutic potential of cannabinoids in women's health.

Immuneering Corporation has reported encouraging results from the Phase 1 segment of its Phase 1/2a clinical trial for IMM-1-104.

Recce Pharmaceuticals Ltd, a company focused on developing synthetic anti-infectives to combat antibiotic resistance and emerging viral threats, has initiated a new phase in its clinical trials.

Preliminary results from a Phase 1b clinical trial of the drug NXP800, developed by Nuvectis Pharma, Inc., have shown promising signs in the treatment of platinum-resistant ARID1a-mutated ovarian cancer.

Nuvation Bio has initiated clinical trials for its first drug-drug conjugate (DDC), NUV-1511.

The company's research has discovered that the cytokines targeted by CAN10, namely IL-1, IL-33, and IL-36, are significantly elevated in the skin samples of systemic sclerosis patients.